Oncology Medical News about Ixabepilone

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Proactive management of adverse events maintains the clinical benefit of ixabepilone
The Oncologist, 06/01/09

Yardley DA - Ixabepilone is an effective agent for treating advanced breast cancer, even in pts who experience disease progression following anthracycline, taxane, and capecitabine therapy. Although this agent is generally well tolerated, by effectively managing adverse events, clinicians can ensure that pts derive the maximum benefit whether given as a single agent or in combination with capecitabine.

Methods

Article reviews the safety profile of single-agent ixabepilone and combination of ixabepilone plus capecitabine therapy
Steps to effectively manage and prevent common adverse events are also outlined

Results

Ixabepilone is generally well tolerated; its toxicity profile does not overlap with that of capecitabine
Common toxicities: peripheral sensory neuropathy and neutropenia
AEs can be effectively managed by:
- monitoring patients and then
- depending on severity, instituting a treatment delay until recovery and
- reducing the ixabepilone dose for subsequent treatment cycles
Ixabepilone dose reductions are recommended for most grade 3 events
Treatment discontinuation is recommended for persistent grade 3 neuropathy or grade 4 nonhematological toxicity
Because ixabepilone exposure is greater in pts with hepatic impairment, dose adjustments and restrictions are recommended according to the degree of hepatic impairment
Pts should be premedicated with oral H1 and H2 antihistamines to prevent hypersensitivity reactions